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Abstract
Background: HIV-associated lipodystrophy syndrome (HALS) is characterized by insulin resistance, abnormal lipid 
metabolism and redistribution of body fat. To date, there has been no quantitative summary of the effects of insulin 
sensitizing-agents for the treatment of this challenging problem.
Methods: We searched MEDLINE, the Cochrane Library, clinical trial registries, conference proceedings and references 
for randomized trials evaluating rosiglitazone, pioglitazone or metformin in patients with evidence of HALS (last update 
December 2009). Two reviewers independently abstracted data and assessed quality using a standard form. We 
contacted authors for missing data and calculated weighted mean differences (WMD) and 95% confidence intervals 
(CI) for each outcome.
Results: Sixteen trials involving 920 patients met inclusion criteria. Rosiglitazone modestly improved fasting insulin 
(WMD -3.67 mU/L; CI -7.03, -0.31) but worsened triglycerides (WMD 32.5 mg/dL; CI 1.93, 63.1), LDL (WMD 11.33 mg/dL; 
CI 1.85, 20.82) and HDL (WMD -2.91 mg/dL; CI -4.56, -1.26) when compared to placebo or no treatment in seven trials. 
Conversely, pioglitazone had no impact on fasting insulin, triglycerides or LDL but improved HDL (WMD 7.60 mg/dL; CI 
0.20, 15.0) when compared to placebo in two trials. Neither drug favorably impacted measures of fat redistribution. 
Based on six trials with placebo or no treatment controls, metformin reduced fasting insulin (WMD -8.94 mU/L; CI -13.0, 
-4.90), triglycerides (WMD -42.87 mg/dL; CI -73.3, -12.5), body mass index (WMD -0.70 kg/m2; CI -1.09, -0.31) and waist-
to-hip ratio (WMD -0.02; CI -0.03, 0.00). Three trials directly compared metformin to rosiglitazone. While effects on 
insulin were comparable, lipid levels and measures of fat redistribution all favored metformin. Severe adverse events 
were uncommon in all 16 trials.
Conclusion: Based on our meta-analysis, rosiglitazone should not be used in HALS. While pioglitazone may be safer, 
any benefits appear small. Metformin was the only insulin-sensitizer to demonstrate beneficial effects on all three 
components of HALS.
Background
While the use of combination antiretroviral therapy
(ART) in individuals infected with human immunodefi-
ciency virus (HIV) has led to substantial declines in dis-
ease-related morbidity and mortality [1], the benefits
have come at a cost. I t is estimated that up to 80% of
patients receiving ART develop some degree of HIV-
associated lipodystrophy syndrome (HALS), character-
ized by insulin resistance, lipid derangements, and unde-
sirable body fat redistribution [2]. The adverse
morphological changes, typified by central fat accumula-
tion and peripheral fat loss, have been associated with
threatened confidentiality, poor medication adherence,
low self-esteem, and reduced quality of life [3,4]. Further,
the metabolic changes associated with HALS may
increase the risk of cardiovascular disease [5-9], a conse-
quence of growing relevance as the life expectancy of
people with HIV continues to improve [10].
A common initial approach to slowing or reversing the
undesirable changes associated with HALS has been to
adjust antiretroviral regimens by eliminating thymidine
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analogues [11-13]. While this approach has been shown
to slow progression, it appears to have less impact on
reversing existing disease. Further, recent reviews have
concluded that the effects of making such ART switches
are generally modest and slow to take effect [11,14,15]. As
a result, focus has shifted to evaluating interventions tar-
geted at specific components of HALS.
Interest in the biguanide metformin and the thiazoli-
dinediones rosiglitazone and pioglitazone has stemmed
in part from the documented efficacy of all three drugs
for improving insulin sensitivity [16,17] and reducing the
progression from impaired glucose tolerance to diabetes
[18-20] in non-HIV populations. In addition, some have
theorized that these drugs might have a special role in
addressing HALS. Metformin has been shown to pro-
mote weight maintenance or loss [20] rather than the
weight gain seen with most hypoglycemic agents and was
recently found to increase HDL3-cholesterol and reduce
immature forms of HDL in patients with HALS [21]. Sim-
ilarly, thiazolidinediones have shown promise because of
their agonist action at peroxisome proliferator-activated-
γ (PPARγ) receptors [22]. PPARγ is known to exhibit
preferential expression in subcutaneous adipose tissue
and has been associated with genetic forms of lipodystro-
phy where PPARγ genes were absent [23]. Further, studies
have found that PPARγ agonists improve insulin sensitiv-
ity and increase subcutaneous adipose tissue mass in HIV
negative populations with lipoatrophic diabetes [24].
While several randomized controlled trials have evalu-
ated insulin-sensitizing agents for the treatment of
HALS, results have been mixed and prior efforts to pool
the data have been limited to qualitative summarizations
[25,26]. In addition, recent data have raised safety con-
cerns about the use of thiazolidinediones in non-HIV
populations[27]. In this paper, we present the first quanti-
tative meta-analysis of randomized-controlled trials eval-
uating the effects of rosiglitazone, pioglitazone or
metformin on insulin, glucose, lipids, body fat redistribu-
tion and adverse events in patients with evidence of
HALS.
Methods
Search Strategy
We searched MEDLINE (1996 to December 2009) using
the following key words: HIV/AIDS, lipodystrophy, insu-
lin sensitivity, thiazolidinediones, rosiglitazone, pioglita-
zone, biguanides and metformin; additionally we
exploded medical subject headings related to these key
words. These results were combined with Phases 1 and 2
of a highly sensitive search strategy recommended for
identifying all randomized trials in Medline [28]. No lan-
guage restrictions were employed. Using similar terms,
we also searched the Cochrane Central Register of Con-
trolled Trials, the Cochrane Database of Systematic
Reviews and the Database of Abstracts of Reviews of
Effects (all from The Cochrane Library, Issue 4, 2009). In
order to locate published articles not identified by our
electronic searches, we manually reviewed references of
studies that met our inclusion criteria as well as any other
articles or reviews that were relevant to our study ques-
tion. To identify unpublished studies, we electronically
searched clinical trial registries including ClinicalTri-
als.gov (December 2009), and manually searched
abstracts from scientific conference proceedings includ-
ing the Infectious Diseases Society of America Annual
Meeting (1997-2009) and the Conference on Retroviruses
and Opportunistic Infections (1997-2009).
Study Selection Criteria
Two reviewers independently evaluated studies for eligi-
bility using the following inclusion criteria: 1) the design
was a randomized controlled trial (RCT); 2) the interven-
tion was either rosiglitazone, pioglitazone or metformin,
3) the comparison was either rosiglitazone, pioglitazone,
metformin, placebo or no treatment; 4) the population
consisted of subjects with one or more features of HIV-
associated lipodystrophy (e.g., body fat redistribution,
insulin resistance, hypertriglyceridemia); and 5) the sub-
jects were followed for a minimum duration of 4 weeks.
We did not employ any exclusion criteria.
Data Abstraction
Two reviewers independently abstracted data from
included studies using a standardized form. Discrepan-
cies were resolved through discussion and review of the
source document. We contacted authors if essential data
was not provided in the published reports.
Quality Assessment
Two reviewers independently assessed each study's meth-
odological quality using the Jadad Scale [29], which
assesses randomization, double-blinding, and attrition
based on seven questions. Scores range from one to five
points with higher quality studies receiving a score
greater than or equal to three. We resolved differences in
quality assessment through joint discussion and review of
the source document.
Outcomes measures
Primary outcomes-fasting insulin and glucose levels
We designated fasting insulin and fasting glucose as our
primary outcomes of interest for several reasons--they
were the most commonly reported measures, have high
clinical familiarity, and are both established clinical
markers for diabetes and cardiovascular mortality [30].
While we had also intended to evaluate one or more for-
mal measures insulin sensitivity, the wide variation in
methodology and reporting across trials precluded quan-
titative summarization.Sheth and Larson BMC Infectious Diseases 2010, 10:183
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Secondary outcomes-fasting lipid levels, body fat 
distribution, adverse events
We designated fasting lipid levels, body fat distribution,
and adverse events as secondary outcomes. To assess the
impact of the insulin-sensitizers on fasting lipid levels we
selected the clinically relevant components--HDL-cho-
lesterol, LDL-cholesterol, and triglycerides. Since the
most meaningful measures of body fat redistribution in
HALS are not known, methods for assessing the morpho-
logic changes varied widely across trials. We selected
body mass index (BMI) and waist to hip ratio (WHR),
because they were widely reported, are clinically familiar,
and have known associations with cardiovascular risk
[31,32]. We also assessed visceral abdominal fat, because
it was the most commonly reported direct measure of
central fat deposition. Unfortunately, methods for
directly measuring peripheral fat wasting were too varied
to permit quantitative summarization. Lastly, in order to
capture clinically important adverse events, we chose the
most consistently defined and reported measure--severe
adverse events, defined as Grade 3 or 4 or resulting treat-
ment discontinuation or study withdrawal.
Data Synthesis
Pooled Summary Analysis
For each outcome of interest, we grouped the reported
findings according to the interventions being compared:
(1) rosiglitazone versus placebo or no treatment (2) piogl-
itazone versus placebo (3) metformin versus placebo or
no treatment, or (4) rosiglitazone versus metformin. All
efficacy outcomes were reported as continuous variables.
We calculated summary weighted mean differences
based on the means and standard deviations of the
change from baseline for each study arm using random-
effects models. When this data was not provided in the
manuscript, we requested missing information from
authors. If requests were declined or not responded to
after at least two inquiries, we attempted to calculate or
estimate the values from data that was available using
established methods [33] (Additional File 1). Appropriate
conversion factors were used to convert the data to uni-
form units. For one study [34], data for fasting insulin and
fasting glucose had to be extrapolated from figures. For
another study [35] that provided all of the needed data for
fasting insulin except the standard deviation around the
change from baseline for the placebo group, we used a
conservative estimate based on the standard deviations
found in other trials. All calculations were performed
using RevMan 4.2.6.
Heterogeneity and Publication Bias
We formally assessed for heterogeneity amongst the trials
contributing to each summary estimate using the chi-
square test and considered a p-value of less than 0.10 to
indicate significant heterogeneity [33]. For each summary
estimate in which heterogeneity was present, we
reviewed the results of the contributing studies in effort
to identify the source of variability. If one or more outliers
could be identified, we performed sensitivity analyses to
investigate how their removal impacted the summary
estimate.
In order to assess for publication bias, we constructed
funnel plots based on our primary outcomes of interest,
fasting insulin and fasting glucose. We visually inspected
the plots for evidence of a paucity of small studies with
negative or less robust results that might suggest publica-
tion bias. All heterogeneity and publication bias assess-
ments were performed using Revman 4.2.6.
Results
Identification of Studies
Of the 56 potentially relevant studies identified by our
search strategy, we excluded 30 studies because they were
not RCTs or did not report any of our outcomes of inter-
est (Additional File 2). After full text review of the
remaining 26 studies, we excluded an additional five stud-
ies because their population, comparison, or outcome of
interest did not meet our inclusion criteria. Further, we
excluded one unpublished abstract (el Bejjani) for which
we were unable to obtain adequate details. This left 16
unique RCTs, represented by 20 published manuscripts
[34-53] for inclusion in the meta-analysis.
Study Characteristics
Additional File 3 presents the characteristics of the 16 tri-
als that met our inclusion criteria. Studies were based in
North America, Europe, and Australia and sample sizes
ranged from 13 to 130. In total, 920 HIV-infected subjects
were studied, consisting predominantly of men (56-100%)
in their forties (mean ages 40-48 years) with mean CD4
counts between 340 and 637 cells/mm3 and varying HIV
lipodystrophy criteria and ART regimens. Study dura-
tions ranged from 8 to 48 weeks and the overall attrition
rates were generally very low. For the three studies that
exceeded 10% attrition [35,37,43], the rates of drop-out
were well balanced between study arms. Fifteen of the 16
trials received a Jadad score greater than or equal to 3, the
threshold indicating higher methodological quality.
Rosiglitazone versus Placebo or No Treatment
Nine unique trials compared rosiglitazone to placebo or
no treatment in 470 subjects over a mean duration of 26
weeks [35-37,41,42,44,47-50,52,53]. As shown in Figure 1,
rosiglitazone resulted in a modest decrease in fasting
insulin (WMD -3.67 mU/L; CI -7.03, -0.31, p = 0.03), but
had no significant effect on fasting glucose. On the other
hand, rosiglitazone had clearly unfavorable effects on
lipid levels (Figure 2). Compared to placebo or no treat-
ment, it significantly increased LDL-cholesterol (WMDSheth and Larson BMC Infectious Diseases 2010, 10:183
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11.3 mg/dL; CI 1.85, 20.8, p = 0.02) and triglycerides
(WMD 32.5; CI 1.93, 63.1), and significantly worsened
HDL-cholesterol (WMD -2.91 mg/dL; CI -4.56, -1.26, p <
0.001). As shown in Figure 3, rosiglitazone had no signifi-
cant effect on any of the body fat outcomes.
Pioglitazone versus Placebo
Two trials evaluated pioglitazone to placebo in 144 sub-
jects over a mean duration of 50 weeks [39,51]. As shown
in Figure 1, pioglitazone had no impact on fasting insulin
or glucose levels. However, in contrast to the negative
lipid effects of rosiglitazone, pioglitazone significantly
improved HDL-cholesterol (WMD 7.60 mg/dL; CI 0.20,
15.0, p = 0.04) (Figure 2). The findings for LDL-choles-
terol were heterogeneous, with the larger trial [51]
reporting no significant difference between the study
arms. As shown in Figure 3, pioglitazone had no signifi-
cant effect on waist-to-hip ratio or visceral adipose tissue.
Compared to placebo, pioglitazone increased the mean
body mass index (WMD 0.60 kg/m2; CI 0.23, 0.97, p =
0.002).
Metformin versus Placebo or No Treatment
Six unique trials compared metformin to placebo or no
treatment in 287 subjects over a mean duration of 27
weeks [35,40,43,45-47,49]. As shown in Figure 1, met-
formin led to a significant decrease in fasting insulin
(WMD -8.94 mU/L; CI -13.0, -4.90, p < 0.001). With
regard to lipid profiles (Figure 2), metformin had no sig-
nificant impact on HDL or LDL-cholesterol, but signifi-
cantly lowered triglyceride levels (WMD -42.87 mg/dL;
CI -73.3, -12.5, p = 0.006). Unlike the thiazolidinediones,
metformin also led to significant reductions in BMI
(WMD -0.70 kg/m2; CI -1.09, -0.31, p < 0.001) and waist-
to-hip ratios (WMD -0.02; CI -0.03, 0.00, p = 0.02) (Fig-
ure 3). While the findings for visceral abdominal fat were
not significant, the point estimate suggested a slight
improvement, which became larger when the heteroge-
neous study [35] was removed.
Rosiglitazone versus Metformin
Three unique trials [34,35,38,47,49] compared rosiglita-
zone and metformin head-to-head in 152 subjects over a
mean duration of 29 weeks (Figure 4). There were no sta-
tistically significant differences between the two drugs
with regard to fasting insulin or glucose levels. All three
lipid findings were less favorable for rosiglitazone when
compared to metformin, including significant reductions
in HDL-cholesterol (WMD -6.94 mg/dL; CI -9.50, -4.37,
p < 0.001). Relative changes in body mass index and
Figure 1 Effects of insulin sensitizing drugs versus placebo or no treatment on fasting insulin and glucose levels in patients with HIV-asso-
ciated lipodystrophy syndrome.
Fasting Insulin (mU/L) Fasting Glucose (mg/dL)
Study N WMD (95% CI) WMD (95% CI)
WMD=weighted mean difference (based on change from baseline for each group), calculated using random effects models
*Test for heterogeneity p=0.02; excluding Tomazic WMD -1.48 (-3.37, 0.41), test for heterogeneity p=0.51, test for overall effect p=0.13
**Test for heterogeneity p=0.002; excluding Tomazic WMD -1.01 (-4.33, 2.31), test for heterogeneity p=0.47, test for overall effect p=0.55
Metformin vs. Placebo or no treatment
Kohli --
Mulligan 53
Tomazic/Silic 30
Martinez 71
Hadigan 25
Saint-Marc 27
Overall                  206   
Rosiglitazone vs. Placebo or no treatment
Blumer                       13
Schindler                   40
Cavalcanti 78
Haider 37
Mulligan 54
Tomazic/Silic 60
Hadigan 28
Carr/Kovacic 108
Sutinen/Yki Jarvinen 30
Overall                395
-3.20 (-6.47, 0.07)*
-6.29 (-14.28, 1.71)** -8.94 (-12.98, -4.90)
Favors Metformin
p<0.001
-3.67 (-7.03, -0.31)
-0.90 (-2.61, 0.80) -1.78 (-5.84, 2.29)
Pioglitazone vs. Placebo
Slama 127
Gavrila 14
Overall 141
No significant difference
p=0.30
No significant difference
p=0.12
No significant difference
p=0.39
Favors Rosiglitazone
p=0.03
No significant difference
p=0.05Sheth and Larson BMC Infectious Diseases 2010, 10:183
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waist-to-hip ratio were also statistically significantly less
favorable with rosiglitazone (WMD 0.80 kg/m2; CI 0.47,
1.14, p < 0.001) and (WMD 0.03; CI 0.01, 0.05, p = 0.01),
respectively.
Severe Adverse Effects
Severe adverse events were defined as Grade 3 or 4 or
leading to treatment discontinuation or study withdrawal
(Additional File 4). Six studies [39,42,46,48,52,53] did not
explicitly report severe adverse event outcomes and four
[34,40,45,49] reported no events in either arm. Based on
the remaining six trials [35-37,39,41,51] in which at least
one severe adverse event was reported, the events were
generally uncommon and varied widely in nature.
Expected side effects (anemia and gastrointestinal (GI)
p r o b l e m s  w i t h  r o s i g l i t a z o n e ;  e l e v a t e d  A L T  l e v e l s  a n d
weight gain with pioglitazone; and GI problems met-
formin) were observed in both intervention and control
study arms. Changes in lactate were not statistically dif-
ferent between study arms in the few studies that report
this outcome.
Heterogeneity and Publication bias
Five of the 31 summary estimates did not pass their
respective tests for heterogeneity, indicating that the
findings of the contributing studies varied beyond what
would be expected by chance alone. Nevertheless, in four
cases we were able to identify a single outlying study that
was responsible; in the fifth case there were only two
studies being combined (Figures 1, 2, 3. In no case did
removing the outlying study result in a change in the
direction or statistical significance of the original sum-
mary estimate. We found no evidence of publication bias
based on visual inspection of funnel plots for the primary
outcome measures fasting insulin and fasting glucose.
Discussion
The findings of our meta-analysis of randomized trials
evaluating insulin-sensitizing drugs in HALS differed
according to the drug studied. We found that rosiglita-
zone modestly improved fasting insulin, but worsened
fasting lipid levels and had no favorable impact on mea-
sures of central adiposity. Conversely while pioglitazone
had no effect on fasting insulin or glucose, it improved
fasting HDL-cholesterol without negative effects on other
lipids. It too had no favorable impact on measures of cen-
tral adiposity. In contrast, metformin favorably impacted
outcomes across all three areas of interest including sta-
tistically significant reductions in fasting insulin, fasting
triglycerides, body mass index and waist-to-hip ratio.
Head-to head trials reinforced the findings of placebo-
and no treatment-controlled trials with metformin dem-
onstrating more favorable impacts on lipids and body fat
Figure 2 Effects of insulin sensitizing drugs versus placebo or no treatment on fasting lipids levels in patients with HIV-associated lip-
odystrophy syndrome.
Fasting HDL (mg/dL) Fasting LDL (mg/dL) Fasting TG (mg/dL)
Study N WMD (95% CI) WMD (95% CI) WMD (95% CI)
1.75 (-0.69, 4.20)
WMD=weighted mean difference (based on change from baseline for each group), calculated using random effects models
*Test for heterogeneity p=0.03; only two studies so source of heterogeneity could not be determined
-32.95 (-95.96, 30.05)
-2.91 (-4.56, -1.26)
36.18 (-49.34, 121.7)*
Favors Placebo 
p<0.001
No significant difference
p=0.16
Favors Placebo
p=0.02
Favors Placebo
p=0.04
-1.77 (-9.39, 5.85) -42.87 (-73.29, -12.45)
Metformin vs. Placebo or no treatment
Kohli 48
Mulligan 53
Tomazic/Silic 30
Martinez 71
Hadigan 25
Saint-Marc 27
Overall                 254   
Rosiglitazone vs. Placebo  or no treatment
Blumer 13
Schindler 40
Cavalcanti 78
Haider 37
Mulligan 54
Tomazic/Silic 60
Hadigan 28
Carr/Kovacic 108
Sutinen/Yki Jarvinen 30
Overall 395
Pioglitazone vs. Placebo
Slama 127
Gavrila 14
Overall 141
7.60 (0.20, 15.00)
11.33 (1.85, 20.82) 32.50 (1.93, 63.07)
Favors Pioglitazone
p=0.04
No significant difference
p=0.31
No significant difference
p=0.41
No significant difference
p=0.65
Favors Metformin
p=0.006Sheth and Larson BMC Infectious Diseases 2010, 10:183
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redistribution, compared to rosiglitazone. Severe side
effects were uncommon with all three drugs.
Overall completeness and applicability of evidence
Though sixteen trials involving over 920 subjects met our
inclusion criteria, the completeness of the data differed
according to intervention. While rosiglitazone and met-
formin were both evaluated in multiple trials, the findings
for pioglitazone were based on only two trials, one of
which had just 14 subjects. With regard to generalizabil-
ity, our inclusion criteria allowed for a wide range of
HALS populations, which varied by both the character
and severity of their lipodystrophy manifestations and the
composition of their ART regimens. Subjects were pre-
dominantly male but females comprised 25-50% of sev-
eral trials. The trial settings and drug dosing were
consistent with those found in clinical practice. Impor-
tant groups that were not represented in the study popu-
lations include adolescents and children with HALS.
Quality of the evidence
In assessing the methodological quality of the included
studies, we found that two trials used "no treatment"
groups rather than placebo controls [46,47,49] and thus
could have been susceptible to performance bias. Both of
these unblinded trials favored the intervention group
more strongly than comparable blinded trials for the fast-
ing insulin and fasting glucose outcomes, thereby possi-
bly inflating these summary estimates. Additionally,
several trials did not adequately describe their method of
randomization or allocation concealment thus precluding
formal assessment of the likelihood of selection bias.
Potential biases in the review process
It is possible that we missed relevant trials, although we
believe this is unlikely based on our systematic search
efforts and no evidence of publication bias. We are aware
of several ongoing trials [54-56] evaluating pioglitazone
which, when available, should allow for a more robust
analysis of the treatment's efficacy and safety.
In regard to our inclusion criteria, it is possible that
allowing populations with diverse manifestations of
HALS and continued use of certain antiretroviral agents
may have contributed to the failure of several studies to
find statistically significant differences for particular clin-
ical outcomes. For example, subjects included based on
isolated derangements in one element of HALS (i.e. cen-
t r a l  a d i po s i t y )  m i g h t  h a v e  be e n  n o r m a l  o r  o n l y  m i l d l y
affected with regard to other elements (i.e. insulin sensi-
tivity) and thus would have had little if any room to bene-
fit with respect to the latter measure. Similarly, because
some antiretroviral agents including specific NRTIs and
PIs, have been shown to increase central adiposity [57]
and down-regulate PPAR receptors [35-37], their contin-
Figure 3 Effects of insulin sensitizing drugs versus placebo or no treatment on body weight and morphology in patients with HIV-associ-
ated lipodystrophy syndrome.
Body Mass Index (kg/m2) Waist to Hip Ratio Visceral Abdominal Fat (cm2)
Study N WMD (95% CI) WMD (95% CI) WMD (95% CI)
0.60 (0.23, 0.97)
-0.70 (-1.09, -0.31)
WMD=weighted mean difference (based on change from baseline for each group), calculated using random effects models
*Test for heterogeneity p=0.05; excluding Haider WMD 0.01 (-0.01, 0.02), test for heterogeneity p=0.42, test for overall effect p=0.60
** Test for heterogeneity p=0.07; excluding Mulligan, WMD -8.34(-23.33, 6.55); test for heterogeneity p=0.11; test for overall effect p=0.27
-0.01 (-0.03, 0.01)
-0.02 (-0.03, 0.00) 
-2.09 (-13.95, 9.78)
-1.04 (-8.71, 6.63)**
Metformin vs. Placebo or no treatment
Kohli 48
Mulligan 53
Tomazic/Silic 30
Martinez 71
Hadigan 25
Saint-Marc 27
Overall               varied
Rosiglitazone vs. Placebo or no treatment
Blumer 13
Schindler 40
Cavalcanti 78
Haider 37
Mulligan 54
Tomazic/Silic 60
Hadigan 28
Carr/Kovacic 108
Sutinen/Yki Jarvinen 30
Overall varied  
Pioglitazone vs. Placebo
Slama 127
Gavrila 14
Overall 141
0.07 (-0.21, 0.26) 0.01 (-0.03, 0.06)* 5.75 (-1.17, 12.66)
No significant difference
p=0.48 
No significant difference
p=0.50
No significant difference
p=0.10
Favors Placebo 
p=0.002
No significant difference
p=0.43
No significant difference
p=0.73
Favors Metformin
p<0.001
Favors Metformin
p=0.02
No significant difference
p=0.79Sheth and Larson BMC Infectious Diseases 2010, 10:183
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ued use could have diluted or negated potential beneficial
effects of the interventions. Nonetheless, despite varia-
tion in ART usage across trials, nearly all summary esti-
mates passed their tests for heterogeneity.
In regards to our analysis, our summary estimates for
the body morphology outcomes may be less robust or
generalizable than other outcomes due to reporting in
only a small subset of studies. Furthermore, while the
most consistently reported morphology-related vari-
ables--BMI, WHR and VAT--capture elements of central
adiposity, they do not specifically address peripheral
wasting, which may be particularly important in the deci-
s i o n  t o  u s e  m e t f o r m i n  i n  p a t i e n t s  w i t h  l i p o a t r o p h y
[43,58].
Agreements and disagreements with other studies or 
reviews
This is the first quantitative meta-analysis evaluating the
effect of insulin-sensitizers in HALS. In 2004 Benavides
[25] sought to summarize the efficacy and safety any
pharmacological therapy for the treatment of HALS, in
particular the effects on fat redistribution. While the
review concluded that "no drug exists to fully ameliorate
or correct the cosmetic changes of HALS", the review was
limited by studies with non-randomized designs and the
inability to quantitatively assess the effects of specific
agents. In 2007 McGoldrick [26] reviewed randomized
trials of statins, fibrates, and insulin-sensitizers for man-
aging dyslipidemias in HIV-infected subjects taking ART.
While concluding that "most studies suggested beneficial
effects and satisfactory safety profiles", the review also
warned that "rosiglitazone appeared to have some detri-
mental effects on lipid profiles". Due to limitations of data
reporting, again no quantitative summarizations were
performed.
When placed in the context of studies evaluating insu-
lin-sensitizers in non-HIV populations, our findings are
consistent with growing safety concerns surrounding the
use of thiazolidinediones, most notably rosiglitazone, due
to increased cardiovascular events[27]. The American
Diabetes Association and the European Association for
the Study of Diabetes now specifically recommend
against the use of rosiglitazone, and while pioglitazone is
still included in the management pathway, is considered
Figure 4 Effects of rosiglitazone vs. metformin on insulin sensitivity, lipid profiles, and morphology in patients with HIV-associated lip-
odystrophy syndrome.
Fasting HDL (mg/dL) Fasting LDL (mg/dL) Fasting TG (mg/dL)
Study N WMD (95% CI) WMD (95% CI) WMD (95% CI)
Rosiglitazone vs. Metformin
Mulligan 53
van Wijk/Coll 31
Tomazic 60
Overall  144   
Favors Metformin
p=0.21
Favors Metformin
p<0.001
Favors Metformin
p=0.11
Rosiglitazone vs. Metformin
Mulligan 53
van Wijk/Coll 31
Tomazic 60
Overall  144   
-1.02 (-3.99, 1.94)
Favors Rosiglitazone 
p=0.50
Fasting Insulin (mU/L) Fasting Glucose (mg/dL)
Study N WMD (95% CI) WMD (95% CI)
0.80 (0.47, 1.14) 0.03 (0.01, 0.05)
Favors Metformin
p<0.001
Favors Metformin
p=0.01
Favors Metformin
p=0.39
Body Mass Index (kg/m2) Waist to Hip Ratio Visceral Abdominal Fat (cm2)
Study N WMD (95% CI) WMD (95% CI) WMD (95% CI)
Rosiglitazone vs. Metformin
Mulligan 53
van Wijk/Coll 31
Tomazic 60
Overall  144   
9.88 (-12.55, 32.32), *
Favors Metformin
p=0.55
WMD=weighted mean difference (based on change from baseline for each group), calculated using random effects models
* Test for heterogeneity p=0.06; ***only two studies so source of heterogeneity could not be determined
1.09 (-2.48, 4.65)
-6.94 (-9.50, -4.37) 7.38 (-4.17, 18.93) 45.05 (-10.50, 100.6)Sheth and Larson BMC Infectious Diseases 2010, 10:183
http://www.biomedcentral.com/1471-2334/10/183
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"less validated"[59]. Additionally our positive findings for
metformin are consistent with a recent review of the
medication in persons at risk for diabetes mellitus which
showed favorable impacts on lipid profiles, insulin resis-
tance, and BMI over a mean study period of 1.8 years in
31 study trials[60].
Implications for research
Ongoing efforts to identify and compare potential inter-
ventions for HALS would benefit from several actions.
First, standardization of the methods used to evaluate
insulin sensitivity and body morphological changes,
including measures of both central adiposity and periph-
eral wasting, would greatly facilitate comparisons across
studies and interventions. In addition, the inclusion of
additional measures such as quality of life and ART com-
pliance could capture important effects not revealed by
changes in laboratory and imaging studies alone. Simi-
larly, longer term studies of the more promising interven-
tions are needed to fully assess whether the short-term
changes in surrogate markers of cardiovascular risk
translate into long-term benefits in reduced cardiovascu-
lar events and mortality.
Implications for practice
The findings of our meta-analysis suggest several impli-
cations for practice. With regard to rosiglitazone, we
believe there is adequate evidence suggesting that the
drug should not be given to patients with HALS. While
pioglitazone did not appear to cause the adverse lipid
problems seen with rosiglitazone, the number of com-
pleted clinical studies is small and more data is needed to
determine whether it is an effective treatment option for
patients with HALS. Lastly, while the evidence showed
that metformin had favorable effects across all three com-
ponents of HALS, whether these short-term, surrogate
changes will translate to long-term clinical benefits is not
known.
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